INO
INOVIO Accelerates Towards PDUFA Target Date for INO-3107 Amidst Strong Commercial Preparations
In a move that underscores its commitment to advancing novel DNA medicines, INOVIO, a biotechnology company dedicated to developing innovative solutions for life-threatening diseases, announced on its fourth quarter and full year 2025 financial results conference call that it remains focused on securing approval for INO-3107, its lead candidate for